Novo Nordisk
Novo Nordisk Q3 Sales Surge on GLP-1 Meds Amid Manufacturing Queries
Since the FDA gave the green light to Novo Nordisk’s GLP-1 weight-loss medication Wegovy over two years ago, the drug ...
Fake Ozempic products seized in EU and UK, Novo Nordisk warns
As Novo Nordisk grapples with the challenges posed by illicit sales of semaglutide, authorities in the UK and Europe have ...
Novo Nordisk acquires Corvidia Therapeutics for $1.3B to compete with Bayer’s Kerendia
Novo Nordisk, riding high on the success of its semaglutide sales, has taken a strategic leap by investing up to ...
Novo Nordisk raises its 2023 outlook for sales and profit, driven by strong diabetes and obesity drugs
Novo Nordisk is experiencing a remarkable surge in its fortunes, primarily driven by the widespread popularity of its diabetes medication ...
Novo’s Ozempic shows promise in kidney disease, but DaVita questions its real-world benefits
Novo Nordisk’s GLP-1 blockbuster Ozempic appears to be making significant strides in the treatment of chronic kidney disease (CKD), potentially ...
FDA warns companies selling unauthorized obesity drugs similar to Wegovy and Mounjaro
The soaring demand for new anti-obesity medications has led to a concerning trend, with various online companies attempting to sell ...
Semaglutide’s Remarkable Success in Kidney Disease Trial Prompts Early Completion
In a recent development surrounding the study of injectable semaglutide’s efficacy in chronic kidney disease, Novo Nordisk has found reason ...
Viatris challenges Novo Nordisk’s patent on diabetes drug semaglutide
In Viatris’ ambitious bid to be the first to introduce generic versions of Novo Nordisk’s blockbuster diabetes and obesity drugs, ...
FDA Approves Novo Nordisk’s Rivfloza, Setting Stage for Market Duel with Alnylam
Novo Nordisk, known for its popular obesity therapy Wegovy, has achieved a significant milestone with the FDA approval of Rivfloza, ...
Novo Nordisk Opposes, Then Joins CMS Drug Pricing Program Amidst Industry Tensions
Novo Nordisk has become the latest player in the biopharmaceutical industry to challenge the drug price negotiation provisions outlined in ...
Big Pharma agrees to negotiate drug prices with Medicare: What does it mean for patients and taxpayers?
Following the recent disclosure by the Centers for Medicare & Medicaid Services (CMS) regarding the list of drugs slated for ...
Big Pharma’s stance on CMS drug price negotiations remains unclear
Following the release of the list of drugs slated for pricing negotiations under the Inflation Reduction Act (IRA) by the ...
Novo Nordisk Foundation Cellerator to boost cell therapy development and production in Denmark
The Novo Nordisk Foundation is embarking on a mission to establish a pivotal “hub” within the cell therapy ecosystem by ...
Eli Lilly Sues 8 Companies for selling fake Mounjaro versions
The surging demand for GLP-1 diabetes and weight loss medications has led to an inevitable influx of knockoff versions. Earlier ...
Novo Nordisk’s semaglutide facility in North Carolina faces FDA scrutiny over quality issues
Novo Nordisk’s shares faced a decline following reports that the FDA had raised concerns about manufacturing issues at the company’s ...
Novo and Lilly’s obesity drugs face barriers of high price and low coverage, survey shows
A recent survey of 100 doctors in the United States who prescribe weight loss medications has revealed that over 75% ...
Novo Nordisk partners with Aspen to boost insulin supply in Africa
Novo Nordisk, a prominent player in the diabetes pharmaceutical industry, is taking significant steps to bolster insulin supplies in Africa. ...
Novo Nordisk’s Wegovy boosts heart health, J.P. Morgan predicts $71B GLP-1 market by 2032
The demand for Novo Nordisk’s obesity medications is surging, with production capacity being the primary limiting factor in the short ...
Novo Nordisk Renews Partnership With Harvard And Broad Institute To Discover New Diabetes And Heart Disease Drugs
Novo Nordisk has announced a collaborative effort with Harvard University and the Broad Institute of MIT to embark on a ...
AstraZeneca’s Farxiga confident of its edge over Novo’s Wegovy in heart failure market
Novo Nordisk’s semaglutide and AstraZeneca’s Farxiga assuming the roles of formidable contenders. The arena is no longer confined to blood ...
Novo Nordisk acquires Embark Biotech for 15 million euros in obesity deal spree
Novo Nordisk has made another move to expand its obesity portfolio, acquiring Embark Biotech for 15 million euros ($16 million) ...
Novo Nordisk’s Semaglutide Triumphs Again: A Heartfelt Victory in the Battle Against Heart Failure
In a remarkable turn of events, the pharmaceutical landscape witnesses Novo Nordisk’s semaglutide, a true star in its arsenal, claiming ...
Novo Nordisk Turns to Thermo Fisher for Production Aid with Obesity Drug Wegovy Amid Catalent Challenges
Novo Nordisk Struggles to Keep Up with High Demand for Wegovy, Enlists Thermo Fisher to Boost Production Amid soaring demand ...
Boehringer’s Obesity Drug with Dual Mechanism Ready for Phase III
Boehringer Ingelheim is forging ahead with its obesity drug candidate, survodutide, moving it into a Phase III program following promising ...
Novo Nordisk and Eli Lilly Ride Obesity and Diabetes Drugs to the Forefront in Q2 Pharmaceutical Performance
As the COVID-19 pandemic surged and waned, the biopharmaceutical industry witnessed a rollercoaster ride of revenue spikes and troughs. However, ...
Wegovy from Novo Nordisk surges, reaching $1 billion in just one quarter
For Novo overall, there’s “a lot to be proud of” in 2023’s second quarter, the company’s head of North American ...
leading obesity medication Wegovy’s ‘best-case scenario’ Novo Nordisk published cardiac results statistics
Source – Novo Nordisk Novo Nordisk has been capitalizing on the momentum generated by its weight loss drug, Wegovy, which ...
A user of well-known GLP-1 medications has filed a lawsuit against Novo Nordisk and Eli Lilly
As Novo Nordisk and Eli Lilly enjoy significant sales from their GLP-1 diabetes and obesity drugs, they also face legal ...
The UK is looking into GLP-1 medications made by Novo Nordisk, AstraZeneca, Lilly, and Sanofi for GLP-1 inhibitor suicide risk
Following the European Union’s lead, the United Kingdom has initiated an investigation into the potential suicide risks associated with popular ...
Medicare prescription coverage for obesity is supported by legislation by Novo Nordisk, Eli Lilly, and Boehringer Ingelheim
Despite the considerable excitement surrounding the potential of new and potent obesity medicines, these drugs remain inaccessible to many Americans ...
